These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23560825)

  • 21. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R; Michailidis P
    Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.
    Godman B; Bishop I; Finlayson AE; Campbell S; Kwon HY; Bennie M
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):469-82. PubMed ID: 23977975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Do generic drugs help control expenditure on hypertension? Apropos of a case].
    García AJ; Martos F; Martín A; Sánchez F
    Gac Sanit; 2004; 18(2):137-44. PubMed ID: 15104975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history.
    Zeng W; Gustafsson LL; Bennie M; Finlayson AE; Godman B
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):157-69. PubMed ID: 25348709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.
    Godman B; Burkhardt T; Bucsics A; Wettermark B; Wieninger P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):475-84. PubMed ID: 19817531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of the 'Better Care Better Value' prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design.
    Baker A; Chen LC; Elliott RA; Godman B
    BMC Health Serv Res; 2015 Sep; 15():367. PubMed ID: 26359265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications.
    Woerkom Mv; Piepenbrink H; Godman B; Metz Jd; Campbell S; Bennie M; Eimers M; Gustafsson LL
    J Comp Eff Res; 2012 Nov; 1(6):527-38. PubMed ID: 24236472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prescribing efficiency of proton pump inhibitors in China: influence and future directions.
    Zeng W; Finlayson AE; Shankar S; de Bruyn W; Godman B
    BMC Health Serv Res; 2015 Jan; 15():11. PubMed ID: 25609265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.
    Bennie M; Godman B; Bishop I; Campbell S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):125-30. PubMed ID: 22280202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi.
    Abuelkhair M; Abdu S; Godman B; Fahmy S; Malmström RE; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):115-24. PubMed ID: 22280201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generic ARBs are coming.
    Harv Heart Lett; 2010 Jul; 20(11):6. PubMed ID: 20815090
    [No Abstract]   [Full Text] [Related]  

  • 32. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction.
    Coma A; Zara C; Godman B; Agustí A; Diogène E; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):569-81. PubMed ID: 19941434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The velocity of antihypertensive effect of losartan/hydrochlorothiazide and angiotensin II receptor blocker.
    Metoki H; Ohkubo T; Kikuya M; Asayama K; Inoue R; Obara T; Hirose T; Sato M; Hashimoto T; Imai Y;
    J Hypertens; 2012 Jul; 30(7):1478-86. PubMed ID: 22573119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
    Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.
    Neutel JM
    Curr Med Res Opin; 2008 Aug; 24(8):2389-401. PubMed ID: 18616863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment.
    Wettermark B; Godman B; Neovius M; Hedberg N; Mellgren TO; Kahan T
    Health Policy; 2010 Mar; 94(3):221-9. PubMed ID: 19879009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends and patterns of five antihypertensive drug classes between 2007 and 2012 in China using hospital prescription data.
    Xu H; He Y; Xu L; Yan X; Dai H
    Int J Clin Pharmacol Ther; 2015 Jun; 53(6):430-7. PubMed ID: 25828638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
    Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
    Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.